Current treatment for colorectal cancer metastatic to the liver

Cromheecke, Michel; Jong, de Steven; Hoekstra, Harald J.

doi:10.1053/ejso.1999.0679

Cited by 61 publications

(35 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of primary colorectal cancer with surgical resection, combined with chemotherapy and radiotherapy in some cases, is effective in many patients. On the contrary, about 10-25% patients had liver metastasis at the time of primary diagnosis and another 20-25% patients developed metachronous liver metastasis [8][9][10][11].…”

Section: Introductionmentioning

confidence: 98%

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Benzoni

Cojutti

Lorenzin

et al. 2006

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Benzoni

Cojutti

Lorenzin

et al. 2006

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“…Despite resection of colorectal cancer, about half of the patients suffer recurrence from metastasis. The liver is the major site of metastasis of colon cancer (3)(4)(5)(6); but only limited numbers of patients who suffer metastasis are candidates for surgery. The alternative method to treat liver metastasis is chemotherapy; therefore, establishment of a liver metastasis model effective for evaluating compounds is important.…”

Section: Introductionmentioning

confidence: 99%

Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice

Hamada

Monnai²,

Kawai³

et al. 2008

Int J Oncol

View full text Add to dashboard Cite

Abstract.To examine the drug efficacy of a novel farnesyltransferase inhibitor (FTI), CH4512600, in vivo, we developed a reliable liver metastasis model of human colon cancer using NOD/Shi-scid IL2Rγ null (NOG) mice. Eleven human colon cancer cell lines were examined for their ability to form diverse metastatic foci in the livers of NOG mice. When inoculated with 10 4 COLO320DM, HCT 116, HT-29, WiDr, LoVo and LS174T cells, liver metastasis was evident in 100% (6/6), 100% (6/6), 88.9% (8/9), 87.5% (7/8), 83.3% (5/6) and 50.0% (3/6) of the NOG mice, respectively. CaCo2, COLO201, LS123, SW48 and SW1417 showed no metastasis when seeded at 10 4 cells even in NOG mice. The mRNA expression levels and genetic mutations of N, H and K-RAS genes, which directly affect the levels of cellular RAS protein that would be molecular target for FTI, were also examined in these six metastatic human colon cancer cell lines for molecular biological and genotypic characteristics. Only three cell lines had a point mutation in the RAS oncogene. LS174T cell line had a point mutation of the K-RAS gene at codon 12 (gly12¡asp; G12D), and HCT 116 and LoVo cell lines had a point mutation of the K-RAS gene at codon 13 (gly13¡asp; G13D). Relative gene expression levels of N, H and K-RAS genes in the HCT 116 cell line were 2.6-5.0-fold lower than that of LS174T and LoVo cell lines. We selected HCT 116 cell line from our liver metastasis model for evaluation of FTI CH4512600 efficacy in vivo.Using the NOG mouse liver metastasis model, we demonstrated the effectiveness of FTI CH4512600 to suppress tumor growth in vivo and to prolong mouse survival significantly from 36.9±2.9 to 50.3±9.4 days.

show abstract

“…The liver is the main site for metastatic disease from colorectal cancer; about 40% of patients develop liver metastases without metastases in other organs. Approximately 25% of these patients are candidates for hepatic resection, and the 5-year survival for patients who undergo liver surgery is 21-48% [1,2]. Brister et al [3] reported a 5-year survival of 21% in patients who had undergone resection for solitary lung metastases.…”

Section: Introductionmentioning

confidence: 99%

CEA, CA 242, CA 19-9, CA 72-4 and hCGβ in the Diagnosis of Recurrent Colorectal Cancer

Carpelan-Holmström¹,

Louhimo²,

Stenman³

et al. 2004

Tumor Biol

View full text Add to dashboard Cite

Objective: The purpose of this study was to compare the utility of serum CEA, CA 19-9, CA 242, CA 72-4 and human chorionic gonadotropin (hCG)β in the follow-up of 102 surgically treated colorectal cancer patients, out of which 40 patients developed clinical recurrence. Methods: In patients with recurrent disease, serum samples were obtained at the time of clinical recurrence, and in the disease-free group, they were obtained postoperatively. The combined use of the markers was evaluated with logistic regression analysis. The sensitivities of the different tumour markers at various specificity levels were compared by receiver operating characteristic (ROC) curve analysis. Results: When the five tumour markers, Dukes stage and location of the primary tumour were evaluated together in the same model, only CEA provided significant diagnostic information (p < 0.0005) in addition to the location of the primary tumour (p = 0.003). The diagnostic information provided by the other serum tumour markers was insignificant, although CA 72-4 approached borderline significance (p = 0.053). ROC curves were constructed and the difference in the values of the area under the curve (AUC) between the different serum tumour markers was determined at the time of clinical recurrence. Of the individual markers, the highest AUC was observed for CEA (AUC = 0.931). The difference in AUC values between CEA and the other tumour markers was highly significant (p ≤ 0.001). Conclusions: CEA had the highest diagnostic accuracy in detecting recurrent colorectal cancer. Inclusion of CA 19-9, CA 242, CA 72-4 or hCGβ in the model did not improve the accuracy, although CA 72-4 approached borderline significance (p = 0.053). Thus, CEA seems to retain its position as the surveillance marker of choice for patients surgically treated for colorectal cancer.

show abstract

Current treatment for colorectal cancer metastatic to the liver

Cited by 61 publications

References 159 publications

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice

CEA, CA 242, CA 19-9, CA 72-4 and hCGβ in the Diagnosis of Recurrent Colorectal Cancer

Contact Info

Product

Resources

About

Current treatment for colorectal cancer metastatic to the liver

Cited by 61 publications

References 159 publications

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Liver resective surgery: a multivariate analysis of postoperative outcome and complication

Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice

CEA, CA 242, CA 19-9, CA 72-4 and hCG&beta; in the Diagnosis of Recurrent Colorectal Cancer

Contact Info

Product

Resources

About

CEA, CA 242, CA 19-9, CA 72-4 and hCGβ in the Diagnosis of Recurrent Colorectal Cancer